CN111955719A - 一种治疗炎症性肠病的特医食品及其制备方法 - Google Patents
一种治疗炎症性肠病的特医食品及其制备方法 Download PDFInfo
- Publication number
- CN111955719A CN111955719A CN202010641788.XA CN202010641788A CN111955719A CN 111955719 A CN111955719 A CN 111955719A CN 202010641788 A CN202010641788 A CN 202010641788A CN 111955719 A CN111955719 A CN 111955719A
- Authority
- CN
- China
- Prior art keywords
- parts
- medical food
- special medical
- inflammatory bowel
- treating inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 56
- 235000013305 food Nutrition 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 27
- 229940054340 bacillus coagulans Drugs 0.000 claims abstract description 27
- 229960002181 saccharomyces boulardii Drugs 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 229920001202 Inulin Polymers 0.000 claims abstract description 17
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 17
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 17
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 16
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 16
- 235000006533 astragalus Nutrition 0.000 claims abstract description 16
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 15
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 14
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 14
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 14
- 239000004310 lactic acid Substances 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 13
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 13
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 13
- 241001523681 Dendrobium Species 0.000 claims abstract description 12
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 63
- 238000000855 fermentation Methods 0.000 claims description 55
- 230000004151 fermentation Effects 0.000 claims description 49
- 238000002156 mixing Methods 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 13
- 241001061264 Astragalus Species 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 210000004233 talus Anatomy 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000010564 aerobic fermentation Methods 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000006872 mrs medium Substances 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims 6
- 241000628997 Flos Species 0.000 claims 3
- 210000000582 semen Anatomy 0.000 claims 3
- 239000009636 Huang Qi Substances 0.000 claims 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 9
- 235000013325 dietary fiber Nutrition 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000000227 grinding Methods 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000027138 indeterminate colitis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种治疗炎症性肠病的特医食品及其制备方法,特医食品包括:甘草1~3份、莲子2~5份、薏苡仁2~5份、金银花1~3份、石斛1~2份、丹参1~2份、野菊花1~2份、红花0.1~0.2份、海带1~2份、黄芪1~3份、茯苓1~3份、菊粉1~3份、红小豆1~2份、布拉氏酵母菌1‑2份、凝结芽孢杆菌1‑2份和乳酸菌1‑2份;制备过程包括:称取、混合、发酵的过程,制备得到的特医食品包含多种药食同源原料组分、高膳食纤维及微生物菌剂,提高了特医食品的治疗效果。
Description
技术领域
本发明涉及益生菌发酵技术领域,更具体地说是涉及一种治疗炎症性肠病的特医食品及其制备方法。
背景技术
炎症性肠病(inflammatoryboweldisease,IBD),包括克罗恩病(Crohn’sdisease,CD)、溃疡性结肠炎(UlcerativeColitis,UC)和未定型结肠炎 (indeterminatecolitis,IC)。近年来,炎症性肠病的发病率不断上升,但尚未有明确的病因,其中遗传因素、环境因素(包括饮食、感染、抗生素和卫生)及其之间复杂的相互作用以及宿主免疫系统导致异常的免疫应答等都可能导致 IBD。
目前,常见的治疗IBD的方式有激素治疗和手术治疗两种,但这两种治疗方法只能暂时缓解IBD的症状;手术治疗前,往往需要术前PN,以降低手术的风险和疾病的治愈率,然而,临床发现,术前PN并不能减少患者术后并发症的发病几率,所以,激素治疗和手术治疗并不能有效控制IBD的发病病程。
研究发现,饮食在IBD发病及治疗中起着关键作用,其中易感人群的饮食和肠道微生物之间的相互作用对IBD的发病和治疗作用已经成为人们的关注和研究热点。现有的关于治疗炎症性肠病的记载中报道:饮食调整仅适用于 IBD患者中非梗阻性狭窄的CD患者,且不能给予患者正常的饮食,应当限定饮食中的纤维数量,并给予大量的叶酸。然而,限制性饮食是远远不能满足患者自身的新陈代谢需要的,这在一定程度上,限制了IBD患者的治愈情况。
因此,如何在满足IBD患者的营养需要的基础上提供一种可以有效治疗 IBD的特医食品是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明提供了一种治疗炎症性肠病的特医食品,该特医食品中包含多种中药组分、高膳食纤维及微生物菌剂,提高了特医食品的效果。
为了实现上述目的,本发明采用如下技术方案:
一种治疗炎症性肠病的特医食品,包括下述重量份配比的组分:
甘草1~3份、莲子2~5份、薏苡仁2~5份、金银花1~3份、石斛1~2份、丹参1~2份、野菊花1~2份、红花0.1~0.2份、海带1~2份、黄芪1~3份、茯苓1~3份、菊粉1~3份、红小豆1~2份、布拉氏酵母菌1~2份、凝结芽孢杆菌1~2份和乳酸菌1~2份。
一种治疗炎症性肠病的特医食品,包括下述最优重量份配比的组分:
甘草1份、莲子2份、薏苡仁3份、金银花1份、石斛1份、丹参1份、野菊花2份、红花0.1份、海带1份、黄芪1份、茯苓1份、菊粉2份、红小豆1份、布拉氏酵母菌1份、凝结芽孢杆菌1份和乳酸菌2份。
以上技术方案达到的技术效果是:
甘草,味甘,性平,无毒,用于胃痛、腹痛及腓肠肌挛急疼痛等,且,甘草所含的次酸能阻断致癌物诱发肿瘤生长的作用;
莲子,味甘,性平,无毒,归脾、肾、心经,具有益肾固精、补脾止泻、养心安神的功能。生莲子肉性平偏凉,长于养心安神,用于虚烦,惊悸,失眠等症;
薏苡仁,味甘,淡,性凉,归脾、胃、肺经,利水渗湿、健脾止泻、清热排脓、除弊,还具备抗肿瘤的效果,尤以脾虚湿盛的消化道肿瘤及痰热挟湿的肺癌更为适宜;
金银花,味甘,性寒;归肺、心、胃经,具有清热解毒,疏散风热的功效;
石斛,味甘,性微寒;归胃、肾经,功能主治:益胃生津,滋阴清热。用于阴伤津亏,口干烦渴,食少干呕,病后虚热,目暗不明;
丹参,味苦,性微寒,无毒,功效:去心腹痼疾结气,腰脊强脚痹,除风邪留热。久服利人。主中恶及百邪鬼魅,腹痛气作,声音鸣吼,能定精、养神定志,通利、落死胎,止血崩带下,调妇人经脉不匀,血邪心烦,恶疮疥癣,瘿赘肿毒丹毒,排脓止痛,生肌长肉;
野菊花,味苦、辛,性微寒,清热解毒,疏风散热,散瘀,明目,降血压。对流行性脑脊髓膜炎,预防流行性感冒、感冒,治疗高血压、肝炎、痢疾、痈疖疗疮都有明显效果;
红花,味辛,性温,归心、肝经,功能主治:活血通经,去瘀止痛。治经闭,症瘕,难产,死胎,产后恶露不行、瘀血作痛,痈肿,跌扑损伤;
海带,味咸,性寒,无毒,归肝、胃、肾三经,功用主治:消痰软坚、泄热利水、止咳平喘、祛脂降压、散结抗癌。用于瘿瘤、瘰疬、疝气下堕、咳喘、水肿、高血压、冠心病、肥胖病;
黄芪,味甘,性微温,归肺、脾、肝、肾经,有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用;但表实邪盛,气滞湿阻,食积停滞,痈疽初起或溃后热毒尚盛等实证,以及阴虚阳亢者,均须禁服;
茯苓,味甘,平,无毒,性温,宁心安神,败毒抗癌,利湿而不伤正气,可治小便不利、水肿胀满、痰饮咳逆、呕逆、恶阻、泄泻、遗精、淋浊、惊悸、健忘等症,所含茯苓酸具有增强免疫力、抗肿瘤以及镇静、降血糖等的作用,也可松弛消化道平滑肌,抑制胃酸分泌,防止肝细胞坏死,抗菌等功效;
菊粉,是植物中的储备性多糖,具有降血糖、降血脂、促进矿物质吸收及调节肠道菌群的效果;
红小豆,性平,味甘、酸,能利湿消肿(水肿,脚气,黄疸,泻痢,便血,痈肿)、清热退黄、解毒排脓。
原料中的协同功效:布拉式酵母菌是一类临床上经常使用的益生菌,它具有优越的耐受人工胃肠液的能力,能够最大程度发挥其益生功效。研究表明,布拉式酵母菌可通过改善肠粘膜屏障及通透性、提高肠道耐受性、调剂免疫功能等对IBD具有改善作用。2016年国家卫计委将凝结芽孢杆菌列入《可用于食品的菌株名单》,凝结芽孢杆菌在维持肠道微生态平衡中起到重要作用。研究表明,凝集芽孢杆菌可有效缓解IBD患者的腹胀、腹痛、并可通过其产生抑菌素有效抑制和清除肠道有害菌。越来越多的研究表明微生态制剂在IBD的临床治疗中扮演重要角色,因此本专利针对性的选取对IBD有缓解及治疗功效的凝结芽孢杆菌、布拉氏酵母菌散菌株和乳酸菌菌株,根据其生长特性形成“好氧+兼性厌氧+厌氧”的复配方式,并充分利用其产生的胞外酶种类和活性差异,选择性的发酵不同原料,充分释放原料中的有益成分。
原料中包含了富含糖类的红小豆、海带、莲子等成分,富含蛋白质类的薏苡仁、茯苓等成分,富含膳食纤维及功能小分子的菊粉、黄芪、丹参等成分,这些成分作为特医食品原料可以有效的发挥食品功能的同时辅助患者治疗和恢复。
一种治疗炎症性肠病的特医食品的制备方法,包括下述步骤:
1)称取:按照上述配比称取原料;
2)将步骤1)称取到的甘草、莲子、薏苡仁和金银花混合,并超微粉碎,制得混合药食同源原料粉末,记为粉末1;
3)向步骤2)制得的粉末1中加入一次发酵培养基,混合均匀,然后接入布拉氏酵母菌及凝结芽孢杆菌,好氧发酵,制得发酵液1,备用;
4)将步骤1)称取的石斛、丹参、野菊花和红花混合,并超微粉碎,制得混合可用于保健食品的中药粉末,记为粉末2;
5)向步骤4)制得的粉末2中加入二次发酵培养基,混合均匀,然后接入乳酸菌,厌氧发酵,制得发酵液2;
6)将步骤1)称取的海带、黄芪、茯苓、菊粉和红小豆混合,并超微粉碎,制得高膳食纤维粉末,记为粉末3;
7)将步骤3)制得的发酵液1和步骤5)制得的发酵液2混合,并进行固液分离;分离得到的上清经超滤浓缩后,进行喷雾干燥,制得上清干粉;分离得到的沉淀经冷冻干燥制得沉淀干粉;然后,将上清干粉、沉淀干粉及粉末3混合,即得治疗炎症性肠病的特医食品;其中喷雾干燥的条件为:入口温度150℃,出口温度75℃;冷冻干燥的条件为-55℃冷冻干燥48小时:
作为本发明优选的技术方案,步骤3)中,一次发酵培养基包括下述重量份配比的组分:10g酵母膏、20g蛋白胨、20g葡萄糖和1000ml水。
作为本发明优选的技术方案,步骤3)中,布拉氏酵母菌及凝结芽孢杆菌的加入量为一次发酵发酵培养基体积的2%,且布拉氏酵母菌及凝结芽孢杆菌的体积比为1:1。
作为本发明优选的技术方案,步骤5)中,二次发酵发酵培养基为MRS 培养基。
作为本发明优选的技术方案,步骤5)中,乳酸菌的加入量为二次发酵发酵培养基体积的2%。
作为本发明优选的技术方案,步骤5)中乳酸菌包括:植物乳杆菌、发酵乳杆菌、干酪乳杆菌、嗜热链球菌、格氏乳杆菌、嗜酸乳杆菌、长双歧杆菌、青春双歧杆菌、婴儿双歧杆菌、两歧双歧杆菌和短双歧杆菌中的一种或任意几种的组合。
作为本发明优选的技术方案,步骤7)中,发酵液1和发酵液2的体积比为1:1~1:3;上清干粉、沉淀干粉及粉末3的质量比为1:1:1~1:3:5。
作为本发明优选的技术方案,步骤2)、步骤4)和步骤6)中粉碎的细度为200-500。
经由上述的技术方案可知,与现有技术相比,本发明达到的技术效果是:
(1))材料优越性:本发明所选用的材料均是药食同源原料或可用于保健食品的中药,用于发酵做医用食品原料安全性高,同时,经过大量文献调研和实验验证,本发明所选的材料均含有对IBD有缓解或者治疗功效的活性成分,用于发酵做医用食品疗效好。
(2)菌株优越性:IBD与肠道菌群的组成和代谢失调相关,益生菌、肠内营养治疗、粪菌移植等饮食及菌群干预手段是未来治疗IBD的重要手段。本发明以益生菌为其中一个切入点,筛选出对IBD有益的菌株,活性菌株的筛选及添加有益于增加本医用食品的疗效。
(3)工艺优越性:本发明的工艺优越性体现在针对不同的原料优选最优发酵菌株,凝结芽孢杆菌胞外淀粉酶较多,当原料中含有莲子、薏苡仁时以凝结芽孢杆菌为发酵菌株;菊花、红花中活性成分易溶于酸性溶液,因此选取乳酸菌为发酵菌株。以上发酵结束后,不进行菌、液分离,充分保留活性成分的同时保留了活性益生菌。
(4)配方优越性:本发明特别甄选富含膳食纤维、维生素的海带、黄芪、茯苓、菊粉、红小豆为原料添加到本医用食品配方中,提高了特医食品的治疗效果。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据提供的附图获得其他的附图。
图1附图为本发明实施例1提供的特医食品对小鼠结肠长度的影响示意图;
图2-1附图为阴性对照组小鼠结肠切片的示意图;
图2-2附图为阳性对照组小鼠和饲喂实施例2特医食品小鼠结肠长度的切片示意图;
图3附图为试验组1-3中小鼠结肠长度的数据图;
图4附图为实施例6中小鼠结肠长度的数据图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种治疗炎症性肠病的特医食品,包括下述重量份配比的组分:
甘草1份、莲子2份、薏苡仁3份、金银花1份、石斛1份、丹参1份、野菊花2份、红花0.1份、海带1份、黄芪1份、茯苓1份、菊粉2份、红小豆1份、布拉氏酵母菌2份、凝结芽孢杆菌2份和乳酸菌1份。
制备方法如下:
1)称取:按照上述配比称取原料;
2)将步骤1)称取到的甘草、莲子、薏苡仁和金银花混合,并超微粉碎至300目,制得混合药食同源原料粉末,记为粉末1;
3)向步骤2)制得的粉末1中加入一次发酵培养基,混合均匀,然后接入布拉氏酵母菌及凝结芽孢杆菌,布拉氏酵母菌及凝结芽孢杆菌的体积比为 1:1,200r/min,37℃,好氧发酵为24小时,制得发酵液1,备用;
4)将步骤1)称取的石斛、丹参、野菊花和红花混合,并超微粉碎至300 目,制得混合可用于保健食品的中药粉末,记为粉末2;
5)向步骤4)制得的粉末2中加入二次发酵培养基,混合均匀,然后接入植物乳杆菌0.5%、发酵乳杆菌0.5%、干酪乳杆菌0.1%、嗜热链球菌0.1%、格氏乳杆菌0.8%的混合菌,37℃,氮气条件下,厌氧发酵时间为48小时,制得发酵液2;
6)将步骤1)称取的海带、黄芪、茯苓、菊粉和红小豆混合,并超微粉碎至300目,制得高膳食纤维粉末,记为粉末3;
7)将步骤3)制得的发酵液1和步骤5)制得的发酵液2按照体积比1: 2的比例混合,并进行固液分离;分离得到的上清经超滤浓缩后,进行喷雾干燥,制得上清干粉;分离得到的沉淀经冷冻干燥制得沉淀干粉;然后,将上清干粉、沉淀干粉及粉末3按照1:2:3的比例混合,即得治疗炎症性肠病的特医食品。
实施例2
一种治疗炎症性肠病的特医食品,包括重量份配比的组分:
甘草3份、莲子5份、薏苡仁2份、金银花3份、石斛2份、丹参2份、野菊花1份、红花0.2份、海带2份、黄芪3份、茯苓3份、菊粉1份、红小豆2份、布拉氏酵母菌1.5份、凝结芽孢杆菌1.5份和乳酸菌1.5份。
制备方法如下:
1)称取:按照上述配比称取原料;
2)将步骤1)称取到的甘草、莲子、薏苡仁和金银花混合,并超微粉碎至300目,制得混合药食同源原料粉末,记为粉末1;
3)向步骤2)制得的粉末1中加入一次发酵培养基,混合均匀,然后接入布拉氏酵母菌及凝结芽孢杆菌,布拉氏酵母菌及凝结芽孢杆菌的体积比为 1:1,200r/min,37℃,好氧发酵为24小时,制得发酵液1,备用;
4)将步骤1)称取的石斛、丹参、野菊花和红花混合,并超微粉碎至300 目,制得混合可用于保健食品的中药粉末,记为粉末2;
5)向步骤4)制得的粉末2中加入二次发酵培养基,混合均匀,然后接入嗜酸乳杆菌0.5%、长双歧杆菌0.5%、青春双歧杆菌0.5%、婴儿双歧杆菌 0.25%、两歧双歧杆菌0.25%的混合菌,37℃,氮气条件下,厌氧发酵时间为 48小时,制得发酵液2;
6)将步骤1)称取的海带、黄芪、茯苓、菊粉和红小豆混合,并超微粉碎至300目,制得高膳食纤维粉末,记为粉末3;
7)将步骤3)制得的发酵液1和步骤5)制得的发酵液2按照体积比1: 1的比例混合,并进行固液分离;分离得到的上清经超滤浓缩后,进行喷雾干燥,制得上清干粉;分离得到的沉淀经冷冻干燥制得沉淀干粉;然后,将上清干粉、沉淀干粉及粉末3按照1:1:1的比例混合,即得治疗炎症性肠病的特医食品。
实施例3
一种治疗炎症性肠病的特医食品,包括下述重量份配比的组分:
甘草2份、莲子3份、薏苡仁5份、金银花2份、石斛1.5份、丹参1.5 份、野菊花1.5份、红花0.15份、海带1.5份、黄芪2份、茯苓2份、菊粉2 份、红小豆1.5份、布拉氏酵母菌1份、凝结芽孢杆菌1份和乳酸菌2份。
制备方法如下:
1)称取:按照上述配比称取原料;
2)将步骤1)称取到的甘草、莲子、薏苡仁和金银花混合,并超微粉碎至300目,制得混合药食同源原料粉末,记为粉末1;
3)向步骤2)制得的粉末1中加入一次发酵培养基,混合均匀,然后接入布拉氏酵母菌及凝结芽孢杆菌,布拉氏酵母菌及凝结芽孢杆菌的体积比为 1:1,200r/min,37℃,好氧发酵为24小时,制得发酵液1,备用;
4)将步骤1)称取的石斛、丹参、野菊花和红花混合,并超微粉碎至300 目,制得混合可用于保健食品的中药粉末,记为粉末2;
5)向步骤4)制得的粉末2中加入二次发酵培养基,混合均匀,然后接入2%短双歧杆菌,37℃,氮气条件下,厌氧发酵时间为48小时,制得发酵液2;
6)将步骤1)称取的海带、黄芪、茯苓、菊粉和红小豆混合,并超微粉碎至300目,制得高膳食纤维粉末,记为粉末3;
7)将步骤3)制得的发酵液1和步骤5)制得的发酵液2按照体积比1: 3的比例混合,并进行固液分离;分离得到的上清经超滤浓缩后,进行喷雾干燥,制得上清干粉;分离得到的沉淀经冷冻干燥制得沉淀干粉;然后,将上清干粉、沉淀干粉及粉末3按照1:3:5的比例混合,即得治疗炎症性肠病的特医食品。
实施例4
用DSS建立IBD小鼠C57BL/6J模型,以患有IBD的小鼠为实验对象,给小鼠分别喂养实施例1低1g、中2g、高3g剂量的药食同源原料。本实验分别设置IBD小鼠模型为阴性对照,记为DSS,以健康小鼠为阳性对照,记为control,连续饲养9天,以其结肠长度为检测对象,结果如图1所示:较比与阴性对照,用实施例1喂养的小鼠结肠长度显著增加,且灌胃高剂量组实施例1的小鼠结肠长度接近于健康小鼠。
在以上模型的基础上,用高剂量3g的实施例2连续喂养IBD小鼠 C57BL/6J,以健康小鼠为阳性对照(control),以IBD模型鼠为阴性对照(DSS),连续饲养15天后,以其结肠切片为检测对象,结果如图2-1和图2-2所示,较比与阳性对照健康小鼠,IBD模型小鼠结肠粘膜不完整,存在不同程度的糜烂,腺体被破坏,排列不整齐,基本丧失正常结构。而灌胃实施例2的小鼠炎症较轻,粘膜较完整,隐窝基本完整,接近正常组织。
实施例5
将实施例1中的凝结芽孢杆菌改为枯草芽孢杆菌,其它操作不变,按照实施例4的方法进行试验,即为试验组1;
将实施例1中厌氧发酵的菌种改为产朊假丝酵母菌种,其它操作不变,按照实施例4的方法进行试验,即为试验组2;
将实施例1中的海带、黄芪、茯苓、菊粉、红小豆分别以(麦苗、玛咖、山药、菊花和小米)代替,按照实施例4的方法进行试验,即为试验组3;
分别测定试验组1-3中,不同剂量组IBD大鼠结肠的长度,结果见附图3。试验组1-3较比与DSS阴性对照组,结肠长度无明显变化,且显著低于正常阳性对照小鼠。
实施例6
直接将实施例1中公开的组分进行混合,制备特医食品,去除其发酵等过程,即为试验组1;
将试验组1按照实施例4的方法进行试验,结果图4所示;如图4所示,依据结肠长度指标,虽然用实施例1中组分饲喂经DSS建模的IBD小鼠有一定的效果,结肠长度增加了30%,但是和实施例增加了46%相比,还具有较大差距,因此,发酵过程必不可缺。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (10)
1.一种治疗炎症性肠病的特医食品,其特征在于,包括下述重量份配比的组分:
甘草1~3份、莲子2~5份、薏苡仁2~5份、金银花1~3份、石斛1~2份、丹参1~2份、野菊花1~2份、红花0.1~0.2份、海带1~2份、黄芪1~3份、茯苓1~3份、菊粉1~3份、红小豆1~2份、布拉氏酵母菌1~2份、凝结芽孢杆菌1~2份和乳酸菌1~2份。
2.根据权利要求1所述的一种治疗炎症性肠病的特医食品,其特征在于,包括下述重量份配比的组分:
甘草1份、莲子2份、薏苡仁3份、金银花1份、石斛1份、丹参1份、野菊花2份、红花0.1份、海带1份、黄芪1份、茯苓1份、菊粉2份、红小豆1份、布拉氏酵母菌1份、凝结芽孢杆菌1份和乳酸菌2份。
3.一种治疗炎症性肠病的特医食品的制备方法,其特征在于,包括下述步骤:
1)按照权利要求1-2任一所述的治疗炎症性肠病的特医食品称取原料;
2)将甘草、莲子、薏苡仁和金银花混合,并超微粉碎,制得混合粉末A;
3)向混合粉末A中加入一次发酵培养基,混合均匀,然后接入布拉氏酵母菌及凝结芽孢杆菌,好氧发酵,制得发酵液A,备用;
4)将石斛、丹参、野菊花和红花混合,并超微粉碎,制得混合粉末B;
5)向混合粉末B中加入二次发酵培养基,混合均匀,然后接入乳酸菌,厌氧发酵,制得发酵液B;
6)将海带、黄芪、茯苓、菊粉和红小豆混合,并超微粉碎,制得混合粉末C;
7)将发酵液A和发酵液B混合,并使用离心机6000rpm离心10分钟进行固液分离;分离得到的上清液经多功能膜分离设备进行超滤浓缩后,进行喷雾干燥,喷雾干燥条件为入口温度150℃,出口温度75℃,最终获得上清干粉;分离得到的沉淀经冷冻干燥制得沉淀干粉,冻干条件为冷阱盘管温度-55℃,冷冻干燥48小时:然后将上清干粉、沉淀干粉及混合粉末C混合,即得治疗炎症性肠病的特医食品。
4.根据权利要求3所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤3)中,一次发酵培养基包括下述重量份配比的组分:10g酵母膏、20g蛋白胨、20g葡萄糖和1000ml水;
5.根据权利要求3所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤3)中,布拉氏酵母菌及凝结芽孢杆菌的加入量为一次发酵培养基体积的2%,且布拉氏酵母菌及凝结芽孢杆菌的体积比为1:1。
6.根据权利要求3所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤5)中,二次发酵发酵培养基为MRS培养基。
7.根据权利要求3所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤5)中,乳酸菌的加入量为二次发酵培养基体积的2%。
8.根据权利要求3所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤5)中乳酸菌包括:植物乳杆菌、发酵乳杆菌、干酪乳杆菌、嗜热链球菌、格氏乳杆菌、嗜酸乳杆菌、长双歧杆菌、青春双歧杆菌、婴儿双歧杆菌、两歧双歧杆菌和短双歧杆菌中的一种或任意几种的组合。
9.根据权利要求3所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤7)中,发酵液A和发酵液B的体积比为1:1~1:3;上清干粉、沉淀干粉及粉末3的质量比为1:1:1~1:3:5。
10.根据权利要求3-9任一所述的一种治疗炎症性肠病的特医食品的制备方法,其特征在于,步骤2)、步骤4)和步骤6)中粉碎的细度为200-500目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010641788.XA CN111955719A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗炎症性肠病的特医食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010641788.XA CN111955719A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗炎症性肠病的特医食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111955719A true CN111955719A (zh) | 2020-11-20 |
Family
ID=73361076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010641788.XA Pending CN111955719A (zh) | 2020-07-06 | 2020-07-06 | 一种治疗炎症性肠病的特医食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111955719A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788737A (zh) * | 2004-12-15 | 2006-06-21 | 北京天施康医药科技发展有限公司 | 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 |
CN102091099A (zh) * | 2007-01-29 | 2011-06-15 | 青岛东海药业有限公司 | 凝结芽孢杆菌制备治疗炎症性肠病药物中的应用 |
CN105029407A (zh) * | 2015-04-14 | 2015-11-11 | 劲膳美生物科技股份有限公司 | 炎性肠病医学配方食品 |
CN107496850A (zh) * | 2017-10-17 | 2017-12-22 | 房学迅 | 一种调节肠道微生态制剂的配方及应用 |
CN109771470A (zh) * | 2019-03-21 | 2019-05-21 | 慕恩(广州)生物科技有限公司 | 一种含益生菌的组合物及其制备方法 |
CN110521939A (zh) * | 2019-09-26 | 2019-12-03 | 天津创源生物技术有限公司 | 一种调节肠道健康的益生菌发酵食品及其制备方法 |
CN110623184A (zh) * | 2019-10-31 | 2019-12-31 | 马轩 | 一种新型中老年专用型保健饮品 |
-
2020
- 2020-07-06 CN CN202010641788.XA patent/CN111955719A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788737A (zh) * | 2004-12-15 | 2006-06-21 | 北京天施康医药科技发展有限公司 | 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 |
CN102091099A (zh) * | 2007-01-29 | 2011-06-15 | 青岛东海药业有限公司 | 凝结芽孢杆菌制备治疗炎症性肠病药物中的应用 |
CN105029407A (zh) * | 2015-04-14 | 2015-11-11 | 劲膳美生物科技股份有限公司 | 炎性肠病医学配方食品 |
CN107496850A (zh) * | 2017-10-17 | 2017-12-22 | 房学迅 | 一种调节肠道微生态制剂的配方及应用 |
CN109771470A (zh) * | 2019-03-21 | 2019-05-21 | 慕恩(广州)生物科技有限公司 | 一种含益生菌的组合物及其制备方法 |
CN110521939A (zh) * | 2019-09-26 | 2019-12-03 | 天津创源生物技术有限公司 | 一种调节肠道健康的益生菌发酵食品及其制备方法 |
CN110623184A (zh) * | 2019-10-31 | 2019-12-31 | 马轩 | 一种新型中老年专用型保健饮品 |
Non-Patent Citations (1)
Title |
---|
郑翠芳等: "布拉酵母对炎症性肠病的治疗作用", 《微生物与感染》, vol. 4, no. 03, 25 September 2009 (2009-09-25), pages 191 - 193 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169923A (zh) | 一种治疗心肌炎的中药组合物及其制备方法 | |
CN102266474A (zh) | 银连解毒胶囊 | |
CN102078584B (zh) | 一种治疗热伤风的中药制剂 | |
CN105663650A (zh) | 一种治疗肺癌的益生菌发酵中药组合物及其制备方法 | |
CN109966427A (zh) | 一种治疗肿瘤及提高机体免疫力的发酵活菌液及其制备方法 | |
CN105942511A (zh) | 一种含青梅的调节肠道菌群的保健食品组合物及制备方法 | |
CN104984292A (zh) | 一种治疗肺炎支原体肺炎的药物组合物及其制备方法 | |
CN105535743A (zh) | 一种益生菌发酵型宣肺止咳合剂及其制备方法 | |
CN105749099B (zh) | 一种治疗胃癌的益生菌发酵中药组合物及其制备方法和应用 | |
CN111955719A (zh) | 一种治疗炎症性肠病的特医食品及其制备方法 | |
CN114601906A (zh) | 一种治疗消化系统疾病的九葉青牌畅清酶益生素口服液及其制备方法和应用 | |
CN103735710B (zh) | 用于治疗奶牛隐性乳房炎的中药组合物及其制备方法 | |
CN106880777A (zh) | 一种益寿养颜保健品及其制备方法 | |
CN109090410A (zh) | 一种活体中药复合益生菌饮品及其制备方法 | |
CN104208547B (zh) | 一种治疗脾虚痰聚型梅核气的中药 | |
CN104840864B (zh) | 一种治疗小儿脾虚型腹泻的中药制剂 | |
CN103860942A (zh) | 用于治疗痰浊结聚型鼻咽癌的药物及其制备方法 | |
CN108355103B (zh) | 治疗幽门螺杆菌相关性胃炎与消化性溃疡的中药组合物 | |
CN107582829A (zh) | 一种防癌抗癌的功能食品 | |
CN105169348A (zh) | 一种促进胰腺切开引流术后康复的中药制剂及制备方法 | |
CN105232879A (zh) | 一种治疗慢性咽炎的中药制剂及其制作工艺 | |
CN115212274A (zh) | 一种治疗慢性结肠炎的生物发酵中药方及制备方法 | |
CN104740162A (zh) | 一种治疗肺炎链球菌性肺炎痰热壅肺证的药物与及其制备方法 | |
CN115634247A (zh) | 一种用于儿童健脾消食的胃药颗粒制备方法 | |
CN117503889A (zh) | 一种治疗脾虚湿热型泄泻的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |
|
RJ01 | Rejection of invention patent application after publication |